

Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	12 months to 31 March 2022	
Previous Reporting Period	12 months to 31 March 2021	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$130,314	Up 15%
Total Revenue	\$130,314	Up 15%
Net profit/(loss) from continuing operations	\$19,848	Up 155%
Total net profit/(loss)	\$19,848	Up 155%
Interim/Final Dividend		
<b>Quoted Equity Securities:</b>		
Amount per Quoted Equity Security	No dividends have been paid on ordinary shares and it is currently not proposed to pay dividends.	
Imputed amount per Quoted Equity Security	Not Applicable	
Record Date	Not Applicable	
Dividend Payment Date	Not Applicable	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.18	\$0.04
A brief explanation of any of the figures above necessary to enable the figures to be understood	<p>Accompanying this announcement are the Group's audited consolidated financial statements for the twelve months ended 31 March 2022. These financial statements and the full year results commentary dated 23 May 2022 provide the balance of information requirements in accordance with NZX Listing Rule 3.5 and Appendix 2.</p> <p>Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).</p>	
Authority for this announcement		
Name of person authorised to make this announcement	Malcolm Tubby	
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd	
Contact phone number	+64 9 488 0232	
Contact email address	malcolm@aftpharm.com	

Date of release through MAP	23 May 2022
-----------------------------	-------------

Audited financial statements accompany this announcement.